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A longitudinal study of HPV detection and
cervical pathology in HIV infected women
H A Cubie, A L Seagar, G J Beattie, S Monaghan, A R W Williams
Objective: To monitor the presence and persistence of high risk (HR) human papillomavirus
(HPV) in cervical brushings from HIV infected women.
Methods: Prospective observational cohort study of HIV infected women.Women were enrolled
from the cohort of 164 HIV infected women who attend the colposcopy clinic at the Edinburgh
Regional Infectious Diseases Unit. A single cervical brush scrape was obtained from 39 women
and two or more samples from 63 women who attended regularly at approximately 6 monthly
intervals. HPV typing was carried out using a commercial hybrid capture assay (HCA). Details of
antiretroviral therapy, cytological assessment, and histological evaluation were made available
and the interrelation with HR-HPV detection analysed.
Results: Abnormal cervical cytology, particularly of low grade, was common in these HIV infected
women. HR-HPV types were detected in 25% of the women with normal cytology, while over 80%
of those with abnormal cytology of any grade were HR-HPV positive. Persistent HR-HPV, as
defined by two or more consecutive HPV positive results, was common and found in 27/63 women
from whom multiple samples were obtained. HR-HPV was detected at high levels whether or not
patients were receiving antiretroviral therapy. Profound immunosuppression was not necessarily
associated with progression of cervical disease and no cases of invasive cervical disease were seen.
Conclusion: While mild dyskaryosis (low grade squamous intraepithelial lesion (LSIL)) and
persistence of HR-HPV are common in HIV infected women in Edinburgh, regular cytological
and colposcopic evaluation with appropriate intervention and treatment appears to limit the pro-
gression of cervical disease.
(Sex Transm Inf 2000;76:257–261)
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Introduction
Both men and women infected with HIV show
an increased frequency of anogenital human
papillomavirus (HPV) infection.1–4 The severity
of HPV associated cervical disease has been
linked to increasing immunological impair-
ment.5–7 HIV infected women with reduced
CD4 lymphocyte counts appear to carry cervi-
cal HPVmore frequently and more persistently
than HIV women whose CD4 counts are not
reduced.8 However, increased cervical disease
is not always found with increasing immuno-
suppression in HIV infected women.9 Norman
and McCarthy point out the major diYculties
in adequate matching of HIV seropositive and
negative study groups and the wide variation in
measures used to assess cervical abnormality
and in 1994 suggested that many of the
diYculties could be circumvented by longitu-
dinal studies over at least a decade.
In the Edinburgh cohort of HIV infected
women a clear association between abnormal
cervical cytology and HIV infection has been
shown,10 with 35% of the women having some
degree of histologically proved cervical in-
traepithelial neoplasia (CIN).11 In addition,
34% of those with CIN had recurrences
associated with reduced CD4 counts within 2
years of treatment.11Recurrent CIN in HIV
positive women has also been noted by
others.12–13 Progression of cervical disease is
most commonly associated with high risk (HR)
human papillomavirus (HPV) types, especially
HPV 16, 18, 31, and 45, which have been
found to be present in more than 90% of cervi-
cal carcinomas worldwide.14
While an increase in anal intraepithelial neo-
plasia and carcinoma in HIV infected men has
been reported in the United States1 and in
Edinburgh (A McMillan, personal communi-
cation), such an increase is not always
observed.4 Similarly, an increase in cervical
carcinoma has been noted in women in the
United States,15 but there is no documented
evidence of an increase in cervical carcinoma in
HIV infected women in Scotland.
The Edinburgh group of HIV infected
women was one of the first well documented
groups where infection arose largely as a result
of injecting drug use and needle sharing. The
majority seroconverted over a fairly short
period of time in the mid-1980s and therefore
provide a good model for the study of the natu-
ral history of HIV associated diseases. The
stable well defined nature of this group
together with their regular attendance at clinics
makes it an ideal population for a prospective
study. We report here the cumulative results
covering a period of 3 years in which we have
studied HPV presence and cervical disease
patterns in relation to clinical management.
Patients and methods
STUDY GROUP AND SAMPLE COLLECTION
The cohort comprises 164 HIV infected
women who have ever attended the colposcopy
clinic at the Regional Infectious Diseases Unit
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in Edinburgh. To date, 106 women have been
enrolled in the study. The age range at
enrolment was 23–55 years, with a mean of 33
years and they are representative of the homo-
geneous population resident in south east
Scotland. Women are invited to attend at 6
monthly intervals for routine review, including
cervical cytology and colposcopic examination,
with cervical punch biopsies where appropri-
ate.
At each attendance, a sample of cervical
brushings was obtained by Cervex brush and
collected into preservative fluid. The sample
was divided into equal aliquots, centrifuged to
deposit cells, and thoroughly resuspended in
transport medium (STM; Digene Diagnostics,
Silver Spring, MD, USA) for HPV hybrid cap-
ture testing (Digene Diagnostics). To date, 298
samples have been received from the cohort.
The analysis presented here is based on 226
samples from the 63 women from whom we
have already received two or more samples. It
excludes 39 women from whom only one sam-
ple has been received and a further 33 for
whom cytology information is not available or
the sample is inadequate. Collection of samples
is continuing and further analysis will be
carried out after 5 years of follow up. Ethical
permission for this study was obtained from
Lothian Health. Patients with histological
evidence of CIN of any grade were treated
using either cold coagulation or, more recently,
loop diathermy in the conventional manner.
CD4 counts, cytology, and histology were
carried out using standard diagnostic proce-
dures and results made available for this study.
Cytology definitions of borderline, mild, and
moderate/severe dyskaryosis follow the UK
convention and are equivalent to ASCUS (but
including some HPV infection), LSIL, and
HSIL respectively in the Bethesda classifi-
cation. Histologically, low grade cervical dis-
ease is reported as koilocytosis (K+)/CIN I and
high grade disease as CIN II/III. HIV RNA
viral load results (copies/ml) obtained diagnos-
tically by the Roche Amplicor system were also
made available.
HPV DETECTION
HPV hybrid capture assay (HCA) is a sand-
wich capture hybridisation assay for qualitative
detection of HR-HPV types, using a specific
HPV RNA probe cocktail and an amplified
chemiluminescence detection system. The
emission of light is measured as relative light
units (RLUs) and is proportional to the
amount of target DNA present. Samples with a
RLU/cut oV value >1 indicate a positive result
for any of the HR-HPV types present in the
probe pool. First generation HCA (HCA I), a
tube based assay detecting nine HR-HPV
types, was used at the beginning of this study
and was replaced by the second generation test
(HCA II) as soon as it became available. This
assay is performed using microtitre plates, has
greater sensitivity, and detects more HPV
types. Wherever possible, testing of early sam-
ples has been repeated using HCA II with the
high risk probe pool for 13 HPV types—16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68.
Results
CYTOLOGICAL AND HISTOLOGICAL RESULTS
Cervical smears in HIV positive patients were
assessed under standard diagnostic conditions.
Where histology was available, there was less
correlation than expected between the cytology
and histology. Review of high grade smears
with a CIN I or negative histology result was
carried out by the same cytopathologist
(ARWW). This led to reclassification of three
cases of moderate to mild dyskaryosis and one
confirmed case of severe dyskaryosis as CIN II.
The original and review data are presented in
figure 1. In the cohort of 164 HIV infected
women, analysis of histological abnormalities
showed that high grade CIN (CIN II/III)
reached a peak in 1990–2 (fig 2) and then
dropped sharply. Low grade CIN (CIN I)
increased between 1987–97 but now also
appears to be decreasing.
DETECTION OF HIGH RISK HPV TYPES
Early samples were tested with HCA I and
retested by HCA II when the sample was still
available. The results with first and second
generation assays were compared. In this small
Figure 1 Scattergram showing correlation between
cytological and histological diagnoses in 39 HIV
seropositive women from whom matching specimens were
obtained.
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Figure 2 Occurrence of cervical intraepithelial neoplasia
(CIN) in HIV infected women attending the Regional
Infectious Diseases Unit, Edinburgh over a 12 year period.
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group of samples, concordance was shown in
77/90 (85.6%). Unlike HCA I, a clear distinc-
tion between positive and negative was ob-
served with HCA II, with no equivocal results
being obtained.
The degree of abnormality observed cyto-
logically together with the percentage of
HR-HPV positive samples found was compa-
rable whether first, last, or all samples were
considered. Twenty three per cent of smears
with normal cytology were HR-HPV positive;
this increased to 70% overall in those with bor-
derline smears, 91% in those with mild
dyskaryosis, and 95% in those with moderate/
severe dyskaryosis (table 1). The highest RLU
indices were generally obtained in samples with
a significant degree of squamous dyskaryosis.
In contrast, 85% of results with negative or
equivocal RLU indices came from samples
with normal cytology (table 2).
RELATION BETWEEN HIV SEROPOSITIVITY, HPV
DETECTION, AND IMMUNOSUPPRESSION
At high HIV RNA viral loads (>50 000 copies
×106/l), the percentage of HR-HPV positive
smears associated with a borderline cytology
result was increased (table 3). With HIV viral
load below 500 copies ×106/l, the percentages
of HR-HPV positive smears were similar to
percentages found in an HIV seronegative
group (data not included; see Discussion).
Four women with high HIV viral load and
HPV positive smears had negative cytology
both at initial assessment and on review.
Investigation of the interaction between
HIV viral load and treatment, HR-HPV, cyto-
logical and histological abnormalities, and
falling CD4 counts was confined to women
from whom multiple samples were obtained.
Forty eight women provided three or more
samples, with six or more samples being
obtained from 12 women. Individual patient
profiles show considerable variation and rep-
resentative examples are shown in figure 3. For
example, P1 has a fluctuating CD4 count, high
HIV viral load despite antiretroviral therapy,
persistent HPV, and continuing high grade
cervical disease. In contrast, P3 has a low CD4
count (<100 cells ×106/l), HIV viral load
currently controlled with triple therapy, but
has persistent HPV and some cervical disease.
P4 has a reasonable CD4 count (140–831 cells
×106/l), despite an increasing HIV viral load
following discontinuation of triple therapy, has
persistent HR-HPV, but no significant cervical
disease. The progression of cervical disease in
the presence of severe immunosuppression
and HPV persistence was a rare event in this
group, with only three examples being ob-
served since the commencement of the study.
In 27/63 women, persistent HR-HPV infec-
tion was noted, as defined by two or more
consecutive HR-HPV positive results. In addi-
tion, HR-HPV has been detected in every
sample taken since enrolment from 16 of these
women. No microinvasive or invasive cervical
cancers have been detected.
Discussion
In this HIV infected cohort, approximately
23% samples from women with cytologically
normal smears were found to harbour HR-
HPV, with 70% of borderline and over 90% of
dyskaryotic smears also HR-HPV positive.
Using HCA II, we have detected a similar per-
centage of HR-HPV positive samples (25%) in
a group of uninfected women with normal
cytology, while the percentage of positives in
uninfected women with cytological abnormali-
ties was lower (48%; data not included). This
agrees with a study from New York5 which
showed a higher prevalence of HPV in HIV
seropositive women, while a similar HPV
prevalence in both HIV positive and negative
women was reported recently in an Italian
study.16
The principal test used in this study was a
second generation HCA, which in our hands
and in other studies has been shown to have
comparable sensitivity to PCR. Clavel et al17
recently suggested that viral load estimated by
HCA was not a reliable indicator of high grade
lesions. We analysed the RLU indices for all
samples (table 2) and found that 75% of sam-
ples with RLU indices between 100–1000 and
100% of those with RLU indices over 1000
showed cytological abnormalities, compared
with 10% of those with RLU indices less than
100, suggesting some correlation of increasing
viral load with increasing cytological abnor-
Table 1 HR- HPV DNA detection in samples of cervical brushings from women infected
with HIV
First sample (%) Last sample (%) All samples (%)
Unsatisfactory 2/5 (40) 1/2 3/8 (38)
Normal 9/36 (25) 11/44 (25) 33/141 (23)
Borderline (ASCUS) 7/12 (58) 4/7 (57) 23/33 (70)
Mild dyskaryosis 6/6 (100) 6/7 (86) 20/22 (91)
Moderate and severe dyskaryosis 3/4 (75) 3/3 (100) 21/22 (95)
Total 27/63 (43) 25/63 (40) 100/226 (44)
Table 2 Relation between degree of HR-HPV positivity and increasing cervical cytology
HCA II result
(as RLU index)
Cervical cytology
TotalU/S Normal Borderline
Mild
dyskaryosis
Mod/severe
dyskaryosis
Negative 5 108 10 2 1 126
Equivocal 0 1 0 0 0 1
Positive (RLUI <10) 3 17 13 6 4 43
Positive (RLUI <100) 0 13 5 4 3 25
Positive (RLUI <1000) 0 2 5 9 12 28
Positive (RLUI >1000) 0 0 0 1 2 3
Total 8 140 33 21 22 226
Table 3 Relation between HIV viral load, detection of
HR-HPV, and cytology
Viral load
(copies ×106/l)
Smear
total Cytology Number
HPV
positivity (%)
<500 32 Neg 24 7 (29)
B/L 4 1 (25)
Mild 3 2 (67)
Mod/sev 1 1 (100)
500–5000 26 Neg 20 6 (30)
B/L 4 3 (75)
Mild 1 0
Mod/sev 1 1 (100)
5000–50 000 37 Neg 23 4 (17)
B/L 6 4 (67)
Mild 3 3 (100)
Mod/sev 5 5 (100)
>50 000 34 Neg 16 4 (25)
B/L 6 6 (100)
Mild 5 5 (100)
Mod/sev 7 7 (100)
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mality using HCA. However, a recent paper by
Swan et al18 concluded that the clinical useful-
ness of HPV quantification required reassess-
ment and was assay dependent.
The high prevalence of some degree of dys-
karyosis and/or CIN in many HIV infected
women confirms our previous findings,10 11
while the relative lack of more severe cervical
disease warrants further study. Indeed, the
progression of cervical disease in the presence
of increasing immunosuppression and HPV
persistence was a rare event in this group with
no microinvasive or invasive cervical cancers
being detected. Invasive cervical cancer was
included in the expanded definition of AIDS
case definition in 199319 and in the same year
in Scotland, two cases were identified in which
invasive cervical cancer was the initial AIDS
defining illness.20 No further cases havebeen
reported however. Similar observations have
been made by other groups,12 questioning the
relevance of including cervical cancer as an
AIDS defining illness in HIV infected women.
It is interesting to speculate that the
development of dyskaryosis and CIN in HIV
positive women may simply be a marker of
widespread immunosuppression rather than
indicating likely progression to malignancy.
Nevertheless, the development of cytological
and histological abnormalities in HIV infected
women appears to be complex and the impact
of prolonged and at times profound immuno-
suppression may bring into play factors and
interactions not seen elsewhere.While HIV has
been suggested as an independent factor in the
development of cervical disease,21 a recent
study from Palefsky’s group22 suggests that HIV
positive women with a CD4 count of <200
cells ×106/l were at highest risk of HPV
infection regardless of HIV viral load. Further-
more, both enhancing and competitive interac-
tions between HIV and viruses such as
cytomegalovirus have been reported in vitro.23
Similarly, cellular changes induced by HIV
could alter the molecular regulation of HPV.
The impact of therapeutic interventions,
Figure 3 Individual patient profiles (P1, P2, P3, P4, and P5), showing variation in HIV viral load,HPV status, cervical cytology, CD4 counts, and
antiretroviral therapy over time since sample collection began.
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antiretroviral therapy, and altered lifestyle on
the development of CIN is diYcult to assess.
However a recent French study24 suggests that
active antiretroviral therapy can result in a
reduced prevalence of squamous intraepithelial
neoplasia (SIL) despite persistent HR-HPV
infection. A reduction in prevalence from 69%
to 53% over a 5 month study period was
observed and included regression from high
grade to low grade lesion and from low grade to
normal. This is an extremely important obser-
vation which requires further study in a larger
group over a longer period.
Recommendations have been made for rou-
tine and regular colposcopy in this population
as a means of screening for cervicovaginal
disease25 and in the United Kingdom the need
to develop national guidelines regarding the
frequency of cervical cytology has already been
identified.26 The Edinburgh cohort of HIV
infected women is a well defined group who
continue to provide a unique opportunity to
study the interactions between HIV, HPV, and
the development of cervical disease.
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